by: David Hutton, OT Staff Reports
According to the company, the VIRGO trial evaluated the safety and efficacy of the investigational twice-daily administration of pilocarpine HCl ophthalmic solution 1.25% in adults with presbyopia. The trial met its primary efficacy endpoint, the company noted.
Allergan, an AbbVie company, today announced that the Phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of pilocarpine HCl ophthalmic solution 1.25%(Vuity) in adults with presbyopia met its primary efficacy endpoint, improving near vision without compromising distance vision at Hour 9 (3 hours after the second drop) on Day 14.
According to the company, additional details of this trial will be presented at future medical congresses and will serve as the basis for a supplemental New Drug Application submission for an optional twice-daily administration to the US Food and Drug Administration (FDA) in the second quarter of 2022. Approved by the FDA in October 2021 for once-daily use, pilocarpine HCl ophthalmic solution 1.25% is the first and only eye drop to treat age-related blurry near vision in adults.
Read More: https://www.ophthalmologytimes.com/view/allergan-announces-positive-topline-phase-3-results-for-presbyopia-therapeutic?utm_source=sfmc&utm_medium=email&utm_campaign=04142022_OT_HEI-22-OPD0444_OME-22-OPD0453_REG-22-OPL0116_ENL_Heidelberg_Omeros%20Cataract%20Therape%20-%20US&eKey=ZG9ubmFAbWFjdWxhcmhvcGUub3Jn
Source: Ophthalmology Times